[ A21-23] Avelumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 19.08.2021
Project no.:
A21-23
Commission:
Commission awarded on 18.02.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy
Indication of minor added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-34 | Avelumab (metastatic Merkel cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-95 | Avelumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G17-09 | Avelumab (metastatic Merkel cell carcinoma) - Benefit assessment according to §35a (1), Sentence 11, Social Code Book V | Commission completed |
| A21-92 | Avelumab (urothelial carcinoma) - Addendum to Commission A21-23 | Commission completed |
Federal Joint Committee (G-BA)
2021-08-19 A G-BA decision was published.